7 past transactions

Kriya Therapeutics

Series C in 2022
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. They have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies

Leyden Labs

Series B in 2022
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Foresight Diagnostics

Series A in 2021
Foresight Diagnostics develops a novel liquid biopsy test for the measurement of minimal residual disease to aid in patient management. They garnered significant partnering interest from multiple pharmaceutical companies in oncology.

Nutcracker Therapeutics

Series B in 2020
Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary, microfluidic, and biochip-based platform. The company specializes in a fully-integrated system for the production of mRNA-therapeutics at the push of a button that enables scalable on-demand experimental and manufacturing capacity, thereby enabling healthcare companies to produce complex multimodal therapeutics at point of care. Nutcracker Therapeutics combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. Its ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips. Igor Khandros and Benjamin Eldridge established the company in Emeryville, California in 2018.

Kriya Therapeutics

Series A in 2020
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. They have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies

Epirium Bio

Series A in 2019
Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function.

Procyrion

Series D in 2019
Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions. Procyrion, has developed a solution: Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance. The company was founded in 2005 and is based in Houston, Texas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.